相关实验视频

Updated: Sep 19, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

丹古伊布克苏 (Danggui Buxue) 蒸与玻利结合,通过抑制CDK2改善了循环胺诱导的骨髓抑制

Kui Li¹, Ruoxia Wu², Ting Zhou³

¹Department of Anorectal Surgery, The First Hospital of Hunan University of Chinese Medicine, Changsha, China.

Cancer biotherapy & radiopharmaceuticals

|June 16, 2025

概括

用醇,特别是其成分甲基素的Danggui Buxue,通过抑制CDK2来对抗化疗诱导的骨髓抑制,从而减少细胞死亡和细胞循环停止.

科学领域:

药理学药理学是指药理学的学科.
传统中国医药传统中国医药
分子生物学分子生物学

背景情况:

骨髓抑制是化疗的重要副作用,影响血液细胞的产生.
丹吉布克苏 (Danggui Buxue) (DBD) 与玻利醇 (DBD&Bor) 结合,是一种具有潜在治疗应用的传统药物.
识别有效的成分和分子标对于优化DBD&Bor在治疗骨髓抑制中的使用至关重要.

研究的目的:

研究DBD&Bor的活性成分和分子点,以缓解骨髓抑制.
评估DBD&Bor及其关键成分对循环胺 (CTX) 诱导的骨髓抑制的疗效.
阐明catechin在缓解骨髓抑制方面的作用机制.

主要方法:

网络药理学被用来识别潜在的活性化合物和标.
在体内研究中使用了CTX治疗的老鼠的免疫血液学,组织病理学和器官指数分析.
在体外测试,包括流细胞计,评估对K562细胞的影响,重点关注细胞亡和细胞循环.
进行了恢复实验和基因表达分析 (CDK2).

主要成果:

鉴定出甲基素,伊索拉姆尼丁和红醇是DBD&Bor.的主要抗髓抑制成分.
在大鼠中,catechin和isorhamnetin逆转了CTX诱导的造血干细胞和血细胞计数的减少.
катехин治疗显著增加了免疫细胞标记物 (CD3,CD4,CD8α) 和减弱了器官损伤.
在体外,catechin通过降低CDK2表达的调节来抑制K562细胞中CTX诱导的亡和细胞循环停止.

结论:

甲基素是DBD&Bor中的主要活性成分,可以有效地缓解CTX诱导的骨髓抑制.
该机制涉及抑制CDK2表达,从而减少细胞亡和细胞循环停止.
作为关键参与者,DBD&Bor具有甲素的作用,显示为治疗化学疗法诱导的骨髓抑制的治疗策略有前途.

关键词:

丹古伊·布克苏 (Danggui Buxue) 蒸的方法波尔尼奥尔 (Borneol) 是一种天然气.卡捷辛是一种可怕的药物.肌肉骨髓抑制的情况网络药理学网络药理学

更多相关视频

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

相关概念视频

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...